Výsledky vyhledávání - "J. S. Zielonka"

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

Autor: Thomas Blevins, Steve Edelman, R. A. Ortmann, Timothy M. Costigan, Melvin J. Prince, J. S. Zielonka, Mark A. Deeg, Robert J. Konrad, Liza L. Ilag, Robyn K. Pollom, W. J. Huster, Priscilla Hollander

Publikováno v: Diabetes, Obesity & Metabolism

Aims To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid sequences, in patients with type 1 o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7cd1d91c5af5483c4f4d9e304aab47
http://europepmc.org/articles/PMC4737399

Zobrazit plný text záznamu

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

Autor: W. J. Huster, Liza L. Ilag, Julio Rosenstock, D. Dahl, Thomas Blevins, Robyn K. Pollom, J. S. Zielonka, Melvin J. Prince

Publikováno v: Diabetes, Obesity and Metabolism. 17:726-733

Aims To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D). Methods This phase III, randomized, open-label, 52-week study enrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0d0c0ad64c596bab70b26c39d749887
https://doi.org/10.1111/dom.12496

Zobrazit plný text záznamu

Autor: Robyn K. Pollom, Liza L. Ilag, Julio Rosenstock, J. S. Zielonka, Priscilla Hollander, Melvin J. Prince, Anuj Bhargava, W. J. Huster

Publikováno v: Diabetes, Obesity and Metabolism. 17:734-741

Aims To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D). Methods Thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfb5347406bc2fb59ea43f7faff6e254
https://doi.org/10.1111/dom.12482

Zobrazit plný text záznamu

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

Autor: T C, Blevins, D, Dahl, J, Rosenstock, L L, Ilag, W J, Huster, J S, Zielonka, R K, Pollom, M J, Prince

Publikováno v: Diabetes, obesitymetabolism. 17(8)

To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in patients with type 1 diabetes (T1D).This phase III, randomized, open-label, 52-week study enrolled patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3ea1fc86a1bc96fccc44807fa91e8df4
https://pubmed.ncbi.nlm.nih.gov/25974640

Zobrazit plný text záznamu

Autor: J, Rosenstock, P, Hollander, A, Bhargava, L L, Ilag, R K, Pollom, J S, Zielonka, W J, Huster, M J, Prince

Publikováno v: Diabetes, obesitymetabolism. 17(8)

To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus(®)) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D).This phase III,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4fbe495567f22e46efc79e32f460218
https://pubmed.ncbi.nlm.nih.gov/25931141

Zobrazit plný text záznamu

CA-022: Efficacité et tolérance de LY2963016 chez des patients atteints de diabète de type 1 et 2 traités antérieurement par l'insuline glargine

Autor: LB Lacaya, Liza L. Ilag, J. S. Zielonka, Roy Daniel Pollom, D. Dahl, I. Benabbad, Irene Hadjiyianni

Publikováno v: Diabetes & Metabolism. 42:A40-A41

Objectif Evaluer l'effet d'un traitement par LY2963016 insuline glargine (LY IGlar) compare a l'insuline glargine (Sanofi-Aventis ; IGlar) dans un sous-groupe de patients anterieurement traites par IGlar (IGlar anterieur) pour un diabete de type 1 da

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2fc6d6655470e85c42f870dd20792865
https://doi.org/10.1016/s1262-3636(16)30154-9

Zobrazit plný text záznamu

Emission tomography of the heart: Principles and applications

Autor: J. S. Zielonka, B. L. Holman

Publikováno v: Cardiovascular Radiology. 2:217-228

Radionuclide methods for evaluation of myocardial ischemia [42, 88] and infarction [42, 43] have become widely available. In addition to providing diagnostic information, these techniques also have predictive value [45]. The accurate interpretation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb5738221ecf6fce1b1b8b8e7e6d929b
https://doi.org/10.1007/bf02552066

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání